000			02337 a2200637 4500
005			20250514003128.0
264		0	_c20010809
008			200108s 0 0 eng d
022			_a0021-9738
024	7		_a10.1172/JCI10128 _2doi
040			_aNLM _beng _cNLM
100	1		_aWigginton, J M
245	0	0	_aIFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. _h[electronic resource]
260			_bThe Journal of clinical investigation _cJul 2001
300			_a51-62 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAngiogenesis Inhibitors _xadministration & dosage
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aCD8-Positive T-Lymphocytes _ximmunology
650	0	4	_aCarcinoma, Renal Cell _xblood supply
650	0	4	_aCombined Modality Therapy
650	0	4	_aDrug Administration Schedule
650	0	4	_aEndothelium, Vascular _xdrug effects
650	0	4	_aFas Ligand Protein
650	0	4	_aImmunologic Factors _xadministration & dosage
650	0	4	_aInjections, Intraperitoneal
650	0	4	_aInterferon-gamma _xphysiology
650	0	4	_aInterleukin-12 _xadministration & dosage
650	0	4	_aKidney Neoplasms _xblood supply
650	0	4	_aMembrane Glycoproteins _xdeficiency
650	0	4	_aMice
650	0	4	_aMice, Inbred BALB C
650	0	4	_aMice, Inbred C3H
650	0	4	_aMice, Knockout
650	0	4	_aMice, Mutant Strains
650	0	4	_aNeoplasm Metastasis
650	0	4	_aNeoplasm Transplantation
650	0	4	_aNeovascularization, Pathologic _xdrug therapy
650	0	4	_aNephrectomy
650	0	4	_aRecombinant Proteins _xadministration & dosage
650	0	4	_aSpecific Pathogen-Free Organisms
650	0	4	_afas Receptor _xphysiology
700	1		_aGruys, E
700	1		_aGeiselhart, L
700	1		_aSubleski, J
700	1		_aKomschlies, K L
700	1		_aPark, J W
700	1		_aWiltrout, T A
700	1		_aNagashima, K
700	1		_aBack, T C
700	1		_aWiltrout, R H
773	0		_tThe Journal of clinical investigation _gvol. 108 _gno. 1 _gp. 51-62
856	4	0	_uhttps://doi.org/10.1172/JCI10128 _zAvailable from publisher's website
999			_c11364564 _d11364564